Key result
Handheld ECG AI detects prior myocardial infarction at a ~9% rate, outperforming clinical scores.
Why the study?
Diagnosis of prior myocardial infarction in low- and middle-income countries is limited by reliance on expert interpretation of diagnostic tests not widely accessible in rural settings.
Does an AI-enhanced handheld ECG algorithm accurately predict prior myocardial infarction compared to standard clinical risk scores in a rural Indian population?
Observational
Does an AI-enhanced handheld ECG algorithm accurately predict prior myocardial infarction compared to standard clinical risk scores in a rural Indian population?
Answers are grounded in this paper and cite their sources.
An AI algorithm using low-cost handheld ECGs can effectively identify patients with prior myocardial infarction in rural India, outperforming standard Western-derived clinical risk scores and offering a cost-effective screening strategy.
Efforts to move care out of hospitals and into the community face a hard constraint: while most medications can be delivered anywhere, diagnosis is still mostly trapped inside the formal health system—clinics, hospitals, and the people and machines inside them. This is especially binding in low- and middle-income countries due to distance, cost, and limited health system capacity. Low-cost data collection devices (e.g., handheld electrocardiograms (ECGs), retinal cameras) are promising, but do not solve the bottleneck: their outputs still require expert interpretation. Artificial intelligence (AI) could turn these raw signals into actionable outputs at scale, but most medical AI is trained in high-income settings and deteriorates in different populations and settings. We assemble a new dataset in rural Tamil Nadu, India that links low-cost device signals to hospital-grade reference testing. We use it to build a proof-of-concept screening tool: an algorithm that predicts the result of a hospital-based reference-standard test (regional wall motion abnormality on echocardiography), using only data from a handheld ECG device (cost: $60). This would allow targeting of secondary prevention medications—high-dose statins, antiplatelet agents, and beta blockers—proven to be cost-effective in both high- and low-resource settings. We evaluate predictive performance and cost-effectiveness of such screening, benchmarking against common clinical risk scores (including the American Heart Association 10-year risk score). In a held-out test set, our model identifies subgroups with rates high enough to make screening very cost-effective: the top 2.5% have a 9.3% rate of evidence consistent with prior heart attack—about six times the base rate—delivering benefits at US$1,999 per life-year saved. The model also flags high-yield patients who would be missed by standard clinical scores, underscoring the limits of transporting Western-derived risk tools to low- and middle-income settings. To enable extensions to other conditions in the dataset, we make all data freely available for research. Institutional subscribers to the NBER working paper series, and residents of developing countries may download this paper without additional charge at www.nber.org.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted an observational in Prior Myocardial Infarction. AI-enhanced handheld ECG screening algorithm vs. Common clinical risk scores was evaluated on Regional wall motion abnormality on echocardiography. An AI algorithm using handheld ECG data identified a high-yield subgroup with a 9.3% rate of prior myocardial infarction, outperforming standard clinical scores and proving highly cost-effective.